Bupropion, the active ingredient in Wellbutrin, has a parent-drug half-life of roughly 8 to 10 hours, but that number undersells how long the drug truly stays active in your body. Bupropion breaks down into three metabolites that are themselves pharmacologically active, and these linger far longer, with half-lives stretching from about 34 to over 60 hours. Because of those metabolites, full clearance from your system after your last dose takes considerably longer than the parent drug’s half-life alone would suggest.
Why the Parent Drug Half-Life Is Only Part of the Story
When you swallow a dose of Wellbutrin, your liver quickly begins converting bupropion into three active metabolites: hydroxybupropion, threohydrobupropion, and erythrohydrobupropion. The parent drug itself clears relatively fast, with a half-life in the 8-to-10-hour range.1Psychopharmacology Institute. Antidepressant Basics Part 1: SSRIs and Bupropion But these metabolites accumulate to higher concentrations than the parent drug and have much longer half-lives. In a study of elderly patients, the measured half-lives were about 34 hours for hydroxybupropion, roughly 39 hours for threohydrobupropion, and around 61 hours for erythrohydrobupropion.2PubMed. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression All three of these metabolites are pharmacologically active, meaning they contribute to the drug’s therapeutic effects and side effects even after the original bupropion molecule has been broken down.
This is why looking at bupropion’s half-life alone gives you a misleadingly short picture. The drug you took may be mostly gone in a day, but the chemicals your body made from it are still circulating and doing work for days afterward.
How Formulation Affects the Timeline
Wellbutrin comes in three formulations: immediate-release (IR), sustained-release (SR), and extended-release (XL). These don’t change the metabolites your body produces, but they do change how quickly bupropion enters your bloodstream and reaches its peak. Immediate-release tablets deliver the drug quickly and are typically dosed two or three times daily. Sustained-release tablets slow things down enough for twice-daily dosing. Extended-release tablets are designed for once-daily use, releasing bupropion gradually throughout the day.
For the extended-release formulation, the effective half-life of the parent drug is closer to 24 hours because the tablet is still releasing bupropion into your gut well after you swallow it. One clinical case report estimated that complete clearance of the extended-release formulation requires roughly 120 hours, or about five days.3CHEST Journal. Fatal Cardiogenic Shock Following Extended-Release Bupropion Overdose: A Case Report That five-day figure aligns reasonably well with basic pharmacokinetic math: it generally takes about five half-lives for a drug to drop below clinically meaningful levels. For the extended-release form with its roughly 24-hour half-life, five half-lives puts you at around five days for the parent drug. The slower metabolites, though, may linger beyond that window.
Total Clearance Time From Your System
If you stop taking Wellbutrin after steady-state dosing, the timeline for full clearance depends on which substance you’re tracking. The parent bupropion will fall below detectable levels within a few days. But because erythrohydrobupropion has a half-life averaging over 60 hours, five half-lives for that metabolite works out to roughly 12 to 13 days. Pharmacokinetic modeling of all the metabolites together suggests terminal half-lives in the range of about 7 to 46 hours, depending on the specific stereoisomer.4PubMed Central. Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers Taking the longest-lived metabolites into account, a reasonable estimate is that bupropion and all its active breakdown products are essentially gone within about two weeks of your last dose.
In practice, you’ll likely stop feeling effects well before that two-week mark. The metabolite concentrations drop with each half-life, so after a few days the levels are low enough that most people won’t notice clinical effects. But for purposes like drug testing or switching medications, those trace metabolite levels can still matter.
Kidney Disease Slows Clearance Significantly
Your kidneys play a bigger role in clearing bupropion than you might expect for a drug that’s heavily metabolized by the liver. In patients with impaired kidney function, bupropion’s blood levels were about 126% higher, and its half-life was 140% longer compared to people with normal kidney function.5PubMed Central. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites That’s a dramatic difference. Interestingly, the metabolite concentrations themselves didn’t change as much, but the ratio of metabolites to parent drug shifted substantially, which suggests that the kidney plays a direct role in eliminating bupropion itself, not just its breakdown products.
If you have kidney problems, this means the drug stays in your system considerably longer. It also means metabolite ratios are different from what clinicians typically expect, which can complicate dose adjustments and monitoring.
Liver Disease and Metabolite Buildup
Since bupropion is metabolized primarily in the liver, you’d expect liver disease to have a major impact. The picture here is a bit nuanced. In people with alcoholic liver disease, the parent drug’s half-life didn’t change much compared to healthy volunteers. However, the half-life of the hydroxybupropion metabolite was significantly prolonged, averaging about 32 hours in the liver disease group versus 21 hours in healthy subjects.6PubMed. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease Overall drug exposure (measured by area under the curve) trended higher in the liver disease group, though the variability between individuals was large enough that the differences didn’t reach clear statistical significance in that small study.
The takeaway is that liver impairment doesn’t necessarily change how fast you break down bupropion, but it does change how long the active metabolites stick around. Since those metabolites drive much of the drug’s effect, this can increase the risk of side effects or toxicity over time, especially with repeated dosing.
Age-Related Changes in Clearance
Older adults tend to accumulate bupropion and its metabolites to a greater extent than younger adults. The half-life of the parent drug is prolonged in the elderly, and the active metabolites build up more during chronic dosing.7Jefferson Journal of Psychiatry. The Efficacy and Toxicity of Bupropion in the Elderly This accumulation is clinically relevant because it can increase the risk of dose-dependent side effects, including seizures. Guidelines generally suggest that while no automatic dose reduction is required for older patients, lower starting doses and closer monitoring are prudent.8Psychopharmacology Institute. Wellbutrin Half-Life: How Long Until It Leaves Your System
Part of the reason for this age-related change is that both liver and kidney function tend to decline with age, even in people without diagnosed organ disease. That double hit slows the elimination of both the parent drug and the metabolites. If you’re older and stopping Wellbutrin, expect the clearance timeline to be on the longer end of the estimates discussed above.
Genetic Variation Can Change How Fast You Metabolize Bupropion
The liver enzyme primarily responsible for converting bupropion into hydroxybupropion is CYP2B6. Genetic variants of this enzyme are common and can meaningfully alter how quickly you process the drug. People who carry certain CYP2B6 variants (like CYP2B6*6 homozygotes) show reduced hydroxylation of bupropion, meaning they produce less hydroxybupropion relative to the parent drug.9PubMed Central. Common polymorphisms of CYP2B6 influence stereoselective bupropion disposition By contrast, people carrying the CYP2B6*4 variant tend to metabolize bupropion faster, producing more hydroxybupropion.
In one study, CYP2B6*6 and *18 variants were associated with roughly a 33% reduction in hydroxybupropion concentrations, and genetic factors combined with sex could account for about half of the variation in hydroxybupropion levels between individuals.10PubMed Central. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state Research in Chinese volunteers found that different CYP2B6 genotype combinations could produce nearly twofold differences in hydroxybupropion blood levels.11PubMed Central. Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects
What this means in practical terms: two people taking the same dose of Wellbutrin can end up with quite different metabolite profiles and, therefore, different effective durations of drug activity. If you’ve ever felt like a standard dose hit you harder or weaker than expected, your CYP2B6 genetics could be a factor. Pharmacogenomic testing can identify your CYP2B6 status, though it isn’t yet routine in most clinical settings for bupropion prescribing.
It’s worth noting that bupropion’s other two metabolites, threohydrobupropion and erythrohydrobupropion, are formed not by CYP2B6 but by a different set of enzymes called carbonyl reductases, which operate in both the liver and intestine.12PubMed Central. Metabolism of bupropion by carbonyl reductases in liver and intestine This means CYP2B6 genetics primarily affect the hydroxybupropion pathway, not the full picture. You could be a fast CYP2B6 metabolizer and still have the other metabolites lingering on their own slow schedule.
Bupropion as a CYP2D6 Inhibitor and What That Means for Other Drugs
Here’s where bupropion’s long metabolite half-lives create a practical problem that extends beyond Wellbutrin itself. Bupropion and its metabolites are potent inhibitors of another liver enzyme called CYP2D6, which is responsible for metabolizing a long list of other medications. In a placebo-controlled study, bupropion treatment converted nearly half of the participants from normal CYP2D6 metabolizers to poor metabolizers.13PubMed. Inhibition of CYP2D6 activity by bupropion That’s a dramatic shift, essentially making your body handle certain other drugs as if you had a genetic enzyme deficiency.
This inhibition is dose-dependent: at higher bupropion doses, about half of patients are converted to a poor-metabolizer status for CYP2D6.14PubMed. Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression Modeling work has shown that bupropion’s metabolites, especially hydroxybupropion, are actually stronger CYP2D6 inhibitors than bupropion itself.15PubMed Central. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model Since those metabolites have half-lives of 34 to 61 hours, the enzyme-inhibiting effect doesn’t vanish the moment you stop taking Wellbutrin. It persists for days afterward.
This matters if you take medications processed by CYP2D6, which include certain antidepressants, beta-blockers, opioid painkillers, antipsychotics, and tamoxifen, among others. If you stop bupropion and immediately adjust the dose of a co-prescribed CYP2D6 substrate, you might overshoot because the inhibitory metabolites are still present. The safer approach is to wait for bupropion’s metabolites to clear before assuming your CYP2D6 function has returned to baseline.
False Positive Amphetamine Drug Tests
One of the more surprising consequences of bupropion’s presence in your system is that it can trigger a false positive result on urine drug screens for amphetamines. In a review of over 10,000 urine drug screens, about 35% of tests that initially screened positive for amphetamines were not confirmed by more precise testing. Among those false positives, 41% of the patients were taking bupropion, making it the single most common cause of false amphetamine results in that population.16PubMed Central. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay
This happens because bupropion’s chemical structure shares enough similarity with amphetamines to cross-react with certain immunoassay tests, particularly the Syva EMIT II assay. Confirmatory testing with more specific methods will correctly distinguish bupropion from actual amphetamines. But if you’re subject to routine drug screening for work, probation, or other reasons, knowing this in advance can save you considerable stress. Bring documentation of your prescription to any drug test. And because the metabolites linger for up to two weeks after stopping, you could test false-positive even after you’ve discontinued the medication.
Bupropion in Breast Milk
For nursing mothers, the question of how long bupropion stays in your system extends to how much reaches the infant through breast milk. A study of breastfeeding women taking bupropion found that when you account for both the parent drug and all three active metabolites, the average infant exposure was about 2% of the mother’s weight-adjusted dose on a molar basis.17PubMed Central. Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use The concentration in breast milk was not affected by the mother’s age, BMI, use of oral contraceptives, the infant’s age, or how frequently the mother was breastfeeding.
That 2% figure is generally considered low, but the long metabolite half-lives mean the exposure is sustained rather than pulsatile. If a breastfeeding mother stops bupropion, the metabolites will continue appearing in breast milk for days. This is worth discussing with a prescriber, particularly because infant liver and kidney function are immature and metabolite clearance may be even slower in newborns than in adults.
Why Individual Variation Is So Wide
One thing that comes through clearly across the research is that bupropion pharmacokinetics vary more from person to person than many other commonly prescribed medications. Your CYP2B6 genotype, kidney function, liver function, age, sex, and which formulation you take all influence the timeline. Two people on the same dose of Wellbutrin XL can have meaningfully different metabolite concentrations and different effective clearance times. The genetic data alone show that CYP2B6 genotype and sex together explain about half the variation in hydroxybupropion levels.10PubMed Central. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state The other half remains unexplained by those factors, which means other variables, including diet, body composition, and co-medications, likely play a role too.
For practical purposes, the best general estimate is that bupropion’s parent compound clears within a few days, but its active metabolites may take up to two weeks to fall to negligible levels. If you have kidney or liver problems, are elderly, or carry slow-metabolizer CYP2B6 variants, your timeline could be longer. If you’re switching medications, undergoing drug testing, or breastfeeding, the metabolite timeline is the one that matters more than the parent drug’s headline half-life.